TELA
TELA Bio Inc.
Company Overview
| Mkt Cap | $47.94M | Price | $0.88 |
| Volume | 82.69K | Change | +7.86% |
| P/E Ratio | -1.2 | Open | $0.82 |
| Revenue | $80.3M | Prev Close | $0.81 |
| Net Income | $-38.8M | 52W Range | $0.50 - $2.20 |
| Div Yield | N/A | Target | $2.25 |
| Overall | 45 | Value | 50 |
| Quality | 55 | Technical | 30 |
No chart data available
About TELA Bio Inc.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Latest News
Tela Bio Eyes Second-Half Ramp After Mixed Quarter
Tela Bio Eyes Second-Half Ramp After Mixed Quarter
Lake Street Keeps Their Buy Rating on TELA Bio (TELA)
TELA Bio posts modest Q1 growth, maintains 2026 outlook
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Irhythm Technologies (IRTC) and TELA Bio (TELA)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TELA | $0.88 | +7.9% | 82.69K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |